Member Info for Eureka01

"Based on the fact a lot of the things he said about DN first time around were correct" He may have got some things right but what about other of his statements such as:

"If the no vote prevails the company will no longer be in their (the directors) hands" 13/10/25

"Just applying for FDA approval would push this over 10p" 29/10/25

"I project a price range of 10p to 20p within the next 12 months" 13/11/25

I would take everything with a very large pinch of salt.🙂

Indeed EC. The sp being down nearly 10% is hardly indicative of a large buy order going through!

Err Fb, I am well aware of the difference. These types of trades are known as Riskless Principal Transactions and do not need to involve the market makers.

The only problem with that is that the trades were for exactly the same amount and went through at exactly the same time. That probably indicates that a broker has acted as an intermediary, buying the shares from one party and simultaneously selling them to another for the same price. He would make his profit from the commissions.

Ok, take this post from the 11th November. "Nissa, I’ll reiterate my position: I project a price range of 10 to 20p within the next 12 months. Most analysts are estimating around 86p, so my forecast is intentionally conservative." There is actually one way out of date valuation of 86p which probably dates from covid times when the sp soared for a while and he has used that to claim that his 10 to 20p is conservative!

DN is not the same as Amers who also claims, without any evidence, that the sp will be in double digits within 12 months.

It's all too obvious.

Another clue then that Amers is being economical with the truth. First he says he would buy 30 million with £100000...wrong. Now he says he would buy 30 million for £45000....wrong. Pumpers and dumpers enderavour to push up the price and then sell into the rise.

So Amers claims he will be buying 30 million shares here in the coming days . There are 1.61 billion shares in issue so that would be nearly 2% of the company. Would someone boast of a very large forthcoming share purchase and risk the sp moving against him? I doubt it.

I will look out for a very large trade any day now but I'm not holding my breath.

Genomics has received a huge boost with a ground breaking breast cancer discovery. Hopefully this will give a boost to other products using genomics such as GDR's test kits.

"Now scientists have developed a genomic test that can spot who needs chemotherapy and who doesn’t. The breakthrough enables doctors to determine which patients can safely skip it, paving the way for a new era of personalised medicine.

https://www.theguardian.com/society/2026/may/29/groundbreaking-genomic-test-spare-breast-cancer-patients-chemotherapy-hormone-therapy

MIKODX, a bit different from you post last month: " I still stick to my opinion which is I think it’s over for shareholders. I do not see the company generating enough revenue before they run out of money again."

It's an old article from the Independent but worth reminding of the future potential of Genedrive's test kits.

"Bill Newman, professor of Translational Genomic Medicine at the University of Manchester who is leading the trial, says that the technology could be used in future to identify how patients are affected by other drugs. "Successful implementation of the gentamicin test will be a first in the integration of a rapid decision-making, genetic-based diagnostic in the UK NHS. It opens the door to getting much better outcomes for a number of other diseases too now that the test is out there."

The success of the Pharmacogenetics to Avoid Loss of Hearing (PALoH) study will save the NHS an estimated £5m every year (including the cost of the test) in cochlear implantations and other hospital costs, according to health economists making up part of the team.

...Mr Newman is convinced that the successful implementation of this trial will open the door to early detection of more common conditions..."It raises the long term possibility of developing a series of tests which might be given to everyone at the age of maybe 40 or 50 (when people start to develop health problems) to look at various genes that we know to be linked to specific drug outcomes. Health passports linked to electronic patient records might then be developed that contain information such as ‘codeine does not work for this patient.'”

https://genedrive.com/worlds-first-emergency-genetic-test-can-save-newborns-from-permanent-deafness-with-simple-cheek-swab/

Those who make wild speculation about the share price over the coming months forget that there is also the likelihood of another fund raise at some point which will act as a drag on the sp. Against that there is much potential good news to come over the next year: FDA submissions, completion of NICE review, conclusion of coronary trial, rollouts across other NHS trusts, regulatory approvals in Europe and the Middle East, commercialisation abroad.

10p in a years time? I very much doubt it but maybe 3p.🙂

AIMHO

Great news! It gets a comment from Zak Mir fwiw:

"No one can say that Mr Nugent does not deserve to be NED at GDR, and his intervention was certainly needed. It is also the case that after a rather long and very often painful journey the company needs new direction and management to see it through to the Promised Land, wherever that may be."

https://www.share-talk.com/rns-hotlist-with-zak-mir-ken-wsbn-epp-aau-mdh-kzg-gdr-bhl-forg-ggp-earn-palm-polb-bsfa/

That adds to the growing number of hospitals in England where the test is being rolled out/piloted:

Southmead Hospital (North Bristol NHS Trust, Bristol)

Salford Royal Hospital (Northern Care Alliance NHS Foundation Trust, Greater Manchester)

Manchester Royal Infirmary (Manchester University NHS Foundation Trust)

Peterborough City Hospital (North West Anglia NHS Foundation Trust)

Doncaster Royal Infirmary, Bassetlaw Hospital, and Montagu Hospital ,(Doncaster and Bassetlaw Teaching Hospitals NHS Trust)

Plus the phased national rollout across all Scottish health boards.

Nissan, the sp has surged a few times over the last few years.

It surged during covid on hopes of a covid test.

It surged again in early 2023 primarily due to positive clinical progress and key regulatory recommendations for its rapid genetic testing products, which were highlighted by significant market interest in February and March of that year.

It surged again in October of last year following DN's involvement.

A buy of 200k has pushed the price up nearly 5%. Normally a small purchase like that would have little effect especially as it was balanced against a 166k sell earlier. That tells me that there is a larger buyer waiting in the wings and MMs want to encourage sellers.

Sure enough a couple of larger sells since and the price is steady. The large buyer is waiting. 🙂

AIMHO

Interesting Buys over the last couple of days:

Thursday: !.043m, 678k. 652k, 1m, 1m, 2.18m

Today (so far): 950k, 500k, 950k,950k, 1m

My guess is that someone, whether it be David Nugent, Robert English or someone else, is accumulating. Profit taking is keeping a lid on the sp thus far enabling the buyer/buyers to get in at or around the existing sp.

I'll be looking out for a TR 1 in the coming days.

There are several possible key drivers for Genedrive looking forward:

1) Commercial Rollout and Adoption: Expanded adoption of the MT-RNR1 and CYP2C19 tests by the NHS in Scotland and the UK, alongside international adoption in Europe and the Middle East.

2) Regulatory Approvals: Success in obtaining FDA clearance (De Novo pathway) for the MT-RNR1 kit, which would allow entry into the US market.

3) Revenue Growth: Continued growth in sales, with the company aiming for further increases in income following doubled revenue for the 2025 financial year.

4) Successful Funding and Funding Solutions: News about securing sustainable financing to extend the company's cash runway—such as potential shareholder loans or successful fundraising initiatives.

5) NICE Recommendation: Positive outcomes from the National Institute for Health and Care Excellence (NICE) Early Value Assessment, which can lead to wider, faster implementation within the NHS.

6) Strategic Partnerships: The successful implementation of partnerships and collaborations with healthcare institutions, such as the 12-month program with Manchester University NHS Foundation Trust.

This has the feel IMO of waiting for a breakout. Up and down over the past several months and then whoosh, when it breaks free from the present range bound parameters.

On dummy trades, 1.1284p to buy and 1.1.0833 to sell.

"Small-cap healthcare shares are rising in early 2026 due to a convergence of stabilizing earnings, increased M&A activity, and a tactical rotation away from overvalued mega-caps. Key drivers include the commercialization of specialized products, such as in the medtech and consumer health sectors, providing a boost to smaller firms with improving cash flows."

Investors Chronicle